

June 24, 2010



Cautionary note concerning forward-looking statements

Certain statements contained herein are forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. Please refer to the section "Cautionary statements" in page 2 of AXA's Document de Référence for the year ended December 31, 2009, for a description of certain important factors, risks and uncertainties that may affect AXA's business. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.

Transaction highlights	Page 4
Strategic rationale & scope	Page 6
Terms & financial impacts	Page 10
Timetable to closing	Page 13
Q&A	Page 15

Transaction Highlights

Opportunity to dispose of the capital intensive parts of UK life business...

Traditional life & pension, IFA protection and corporate pension businesses, and annuities businesses to be sold to Resolution

...and to focus on capital light and higher margin business in the UK

Leading AXA Wealth management and AXA Direct protection businesses with competitive advantage to be retained

Consideration

Sale price of £2.75 billion o/w £2.25⁽¹⁾ billion in cash and £0.5 billion in senior Deferred Consideration Note ("DCN") issued by Resolution Ltd

Expected timetable

- Resolution Ltd shareholders' vote mid-July
- Resolution Ltd rights issue process starting immediately thereafter
- Closing and payment of consideration to AXA expected in Q3 2010

(1) Including £26m (plus interest) to be paid on completion of certain steps in the agreed post-completion reorganisation



Transaction highlights	Page 4
Strategic rationale & scope	Page 6
Terms and financial impacts	Page 10
Timetable to closing	Page 13
Q&A	Page 15

Strategic rationale of the transaction for the Group

Focus on businesses with the right combination of scale, competitive position, growth prospects and profitability

Use of proceeds:


Further improving our capital & growth profile

- 1 Redeploy capital more efficiently throughout the group across:
 - Business lines (health, protection, UL ...)
 - Geographies (high-growth markets...)
- 2 Continue to invest in the development of the UK Wealth management business

While maintaining a strong balance sheet

Strategic rationale of the transaction for AXA UK Life

In continuity of strategic repositioning of AXA UK life business in recent years



Scope of the transaction


Business retained vs. business sold

Retained

- AXA Wealth
 - ► AXA Winterthur Wealth Management
 - AXA Wealth International
 - ► Elevate wrap platform
 - Architas Multi-Manager
 - + Bancassurance distribution
- Sun Life Direct
 - ▶ Direct protection business
- Bluefin Advisory Services


Sold

- Legacy life & pensions book (including annuities)
- Corporate Pensions
- IFA Protection













^{*} Including £14m APE of non-modelled businesses

^{**} Including mutual funds total net inflows on retained business amounted to £+2.1 billion $8-\mathsf{AXA}-\mathsf{June}\ 2010$

AXA UK business profile going forward

AXA remains strongly committed to the UK market

Build on UK market franchises

Wealth **Management**

£15bn AUM today £45bn in 2015





- AXA Wealth IFA 14% market share with 5 Star service record 1
- 20% IFA offshore market share ²
- RDR* ready business model
- Bancassurance distribution



- £1bn Assets under Management + 550 IFAs signed up
- Platform delivers mutual funds, ISAs, Pension account, offshore bond and shortly an onshore bond



- #6 UK multi-manager since launch in 2008 ³
- Assets under Management of £3bn
- Unique Mosaic investment process ⁴

Health & **Protection**






- #2 UK Healthcare PMI provider ⁵
- # 1 in direct to consumer protection market ⁶
- Combined 5 million customers

General Insurance





- swiftcover.com # 4 in UK Insurance market 7
 - Direct motor and household 950,000 policy holders

Broker & Advisory



- # 2 UK SME insurance broker 8
- Corporate Adviser firm of the year 2009 and 2010 9
- RDR ready Private Advisory business

ABI Statistics 2010

Laing Buisson / Private Healthcare report 2009

Lipper Feri 2010

Swiss Re Term & Health Watch 2010


Retail Distribution Review


Innovation Awards 2010



Transaction highlights	Page 4
Strategic rationale & scope	Page 6
Terms and financial impacts	Page 10
Timetable to closing	Page 13
Q&A	Page 15

Key transaction parameters






- (1) Including £26m (plus interest) to be paid on completion of certain steps in the agreed post-completion reorganisation
- (2) FY09 EV as published by AXA, adjusted for AAPH shares (£0.7 billion) and the business retained. Based on Resolution Ltd methodology and assumptions this corresponds to 0.80x a pro-forma EV reflecting adjustments mainly on liquidity premium and cost of capital.
- (3) FY09 underlying earnings adjusted for £-106m one-off gain related to internal restructuring of an annuity portfolio, for £+16m dividend on AAPH shares and for the business retained



Financial impacts on AXA Group



Q&A	Page 15
Timetable to closing	Page 13
Terms and financial impacts	Page 10
Strategic rationale & scope	Page 6
Transaction highlights	Page 4

Expected timetable of closing of transaction

Key dates	Events
End of June	Publication of Resolution Ltd's prospectus
Mid July	Resolution Ltd shareholders' vote (50% support needed)
Immediately thereafter	Start of Resolution Ltd rights issue offer period
Early August	Closing of Resolution Ltd rights issue
End of Q3 2010	Closing, payment of purchase price

This transaction is subject to certain covenants and conditions customary for a transaction of this nature, including the approval of the shareholders of Resolution Ltd and the receipt of regulatory approvals.



Q&A	ı	Page 15
Timetable to closing		Page 13
Terms and financial impacts		Page 10
Strategic rationale & scope		Page 6
Transaction highlights		Page 4

Q&A

